POSITRIGO

Positrigo, headquartered in Zurich, Switzerland, was founded in 2018 as a spin-off of ETH Zurich. The company develops NeuroLF, an ultra-compact, dedicated brain Positron Emission Tomography (PET) scanner that makes functional brain imaging accessible for diagnosing Alzheimer's disease, dementia, neuro-oncology, epilepsy, and movement disorders. NeuroLF has received both FDA clearance and CE Mark, and Positrigo has expanded into the U.S. and multiple European markets.